Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$38.40
+0.15 (+0.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-181.1M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$29.1B
P/E
3.4x
↓EV/EBITDA
2.8x
↓ROE
35.2%
↑Gross Margin
41.0%
↓Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+25.5%
FCF CAGR
—
FCF margin
-11.9%
FCF / Net income
-0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.52B · net income $9.32B · FCF $-181.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.52B | $1.52B | $1.62B | $1.39B | $767.7M |
| Net Income | $9.32B | $9.32B | $-1.10B | $-995.4M | $102.2M |
| EBITDA | $11.95B | $11.95B | $-781.4M | $-765.8M | $-473.2M |
| EPS | — | — | -1.48 | -1.43 | 0.15 |
| Gross Margin | 41.0% | 41.0% | 46.3% | 44.3% | 52.9% |
| Operating Margin | -23.9% | -23.9% | 14.5% | 5.6% | 37.0% |
| Net Margin | 614.9% | 614.9% | -68.2% | -71.4% | 13.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.36 | 0.28 | 0.18 |
| Current Ratio | 0.93 | 0.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-181.1M | $-181.1M | $216.2M | $-1.14B | $-197.4M |
| Returns | |||||
| ROE | 35.2% | 35.2% | -6.1% | -5.0% | 0.5% |
| Valuation | |||||
| P/E | 3.36 | 3.36 | — | — | 261.55 |
| EV/EBITDA | 2.77 | 2.77 | — | — | — |
| P/B | 1.08 | 1.08 | 1.69 | 1.49 | 1.40 |
| Growth & Yield | |||||
| Revenue Growth | -6.3% | -6.3% | 16.1% | 81.6% | — |
| EPS Growth | — | — | -3.7% | -1037.5% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.48 → n/d
Residual
+5.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.